Michael Makris: NovoNordisk Has Applied to the FDA for Approval of Mim8
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared on LinkedIn:
‘‘NovoNordisk has applied to the FDA for approval of Mim8, a bispecific antibody which will be a direct competitor to emicizumab (Hemlibra).
The data we have seen presented at scientific meetings and published are strong, and suggest that approval is likely to be given.”
Read the full article here.
Article: Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors
Stay updated on the emerging in the field of Hemophilia with Hemostasis Today.
-
Sep 30, 2025, 11:43Wolfgang Miesbach: Jan Astermark at the BIC 2025 Presented Potentially the First Oral FVIII Mimetic Treatment for Hemophilia A
-
Sep 30, 2025, 06:43Sara García Barcenilla: What Better Way to Celebrate ''World ITP Day'' Then With The Interview of Nora Butta and Daniel Aníbal García-Diego
-
Sep 30, 2025, 06:42Courtney Battaglia: AFib Can Cause Racing Heartbeat or Fatigue and Also Raises The Risk of Stroke!
-
Sep 29, 2025, 22:44Pall T. Onundarson on Correlation Between Plasma Levels of DOACs and Both Thromboembolic and Bleeding Events
-
Sep 29, 2025, 16:19Xue Feng Presented Her Work on AAV Vector–Based Gene Therapy
-
Sep 30, 2025, 06:45Robert Mikulik and Colleagues Show Differences in Acute Ischemic Stroke Treatment
-
Sep 30, 2025, 06:40Cihan Ay: Can AI Match Thrombosis Experts?
-
Sep 29, 2025, 19:56Luisa Hora de Carvalho and Colleagues Highlight The Challenges in Evaluating Thromboembolic Risk in Acute Leukemia
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 11:48Nan van Geloven on Platelet Transfusion Outcomes in Preterm Infants With Severe Thrombocytopenia
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 19:39Louise Bannon: Today is World Heart Day, And It's Deeply Personal For Me
-
Sep 29, 2025, 16:16Maxime Dely: Improving Collections for Better Patient Outcomes
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia